Summit Therapeutics, Inc. (SMMT)
17.60
+0.48
(+2.77%)
USD |
NASDAQ |
Sep 04, 16:00
17.59
-0.02
(-0.09%)
After-Hours: 20:00
Summit Therapeutics Research and Development Expense (Quarterly) : 157.73M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 157.73M |
| March 31, 2026 | 132.62M |
| December 31, 2025 | 147.29M |
| September 30, 2025 | 131.10M |
| June 30, 2025 | 208.02M |
| March 31, 2025 | 51.26M |
| December 31, 2024 | 51.40M |
| September 30, 2024 | 37.72M |
| June 30, 2024 | 30.80M |
| March 31, 2024 | 30.87M |
| December 31, 2023 | 24.80M |
| September 30, 2023 | 15.32M |
| June 30, 2023 | 9.451M |
| March 31, 2023 | 9.883M |
| December 31, 2022 | 5.169M |
| September 30, 2022 | 16.83M |
| June 30, 2022 | 8.776M |
| March 31, 2022 | 20.31M |
| December 31, 2021 | 22.86M |
| September 30, 2021 | 19.69M |
| June 30, 2021 | 23.67M |
| March 31, 2021 | 18.12M |
| December 31, 2020 | 11.84M |
| September 30, 2020 | 13.42M |
| Date | Value |
|---|---|
| June 30, 2020 | 13.26M |
| March 31, 2020 | 12.19M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | 11.97M |
| October 31, 2018 | 10.37M |
| July 31, 2018 | 12.84M |
| April 30, 2018 | 15.94M |
| January 31, 2018 | 13.21M |
| October 31, 2017 | 9.761M |
| July 31, 2017 | 8.528M |
| April 30, 2017 | 6.283M |
| January 31, 2017 | 5.948M |
| October 31, 2016 | 5.078M |
| July 31, 2016 | 7.528M |
| April 30, 2016 | 6.861M |
| January 31, 2016 | 7.416M |
| October 31, 2015 | 6.934M |
| July 31, 2015 | 6.554M |
| April 30, 2015 | 4.720M |
| January 31, 2015 | 4.305M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 0.917M |
| Kezar Life Sciences, Inc. | 1.545M |
| Protara Therapeutics, Inc. | 16.88M |
| Clene, Inc. | 3.135M |